OUR MANAGEMENT TEAM
Alan Tuchman, MD, MBA
Alan Tuchman, MD, MBA, has been with MedPro Investors since its formation.
He brings over 35 years of medical experience, and a wealth of healthcare
Dr. Tuchman’s successful tenure in the medical and investment fields include his governance as Executive Chairman at Neurophysics, Inc., a manufacturer of nuclear brain scanners; Managing Director of Xmark Funds, a biotechnology investment firm; and Principal of his own healthcare consulting firm. Dr. Tuchman is a clinical professor of neurology at New York Medical College and is in private practice in Manhattan.
Isaac Treitel has over fifteen years experience identifying promising early-stage
life science and technology companies and providing them with development
and financial support. As a Director of TriState Ventures and co-founder of
MedPro Investors LLC, Isaac evaluates investment opportunities, develops
strategic partnerships, and advises portfolio companies on operational and financial strategy. His prior experience includes webtool and software development, as well as investment analysis. Isaac began his career as a Research Analyst for a large pension fund before focusing on what he found most rewarding, the nurturing and financing of smaller companies.
Mitchell Glass, MD
Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.
After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.
Tom DiBartholomeo, MD
Tom DiBartholomeo has over 20 years of healthcare delivery and investment
analysis. In addition to practicing diagnostic and interventional radiology he has
served as an analyst for a hedge fund, served on medical advisor boards for
private equity and venture capital funds in addition to providing consultation to early stage companies. He is a founder of a healthcare information technology company as well. His guiding principle as a physician and analyst/investor is continuous improvement in patient care. As a healthcare investor analyst, he sources and evaluates medical device and diagnostic, Biotechnology, and therapeutics companies for potential investment. As an advisor, he works with companies building regulatory and commercialization pathways, and educate sales/marketing teams on product utility to medical practices and value for patient users.
Tim Hirst, PhD
Tim is the Chairman & CEO of GPN Vaccines. He has extensive expertise in the
life sciences, executive management and venture capital investment. Tim was
previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund, the Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. He is an active angel investor working with investment groups throughout Australia and US. Tim is also Chairman of Gamma Vaccines Pty Ltd, Chairman of Brain Changer Pty Ltd, Director of Emudent Technologies Pty Ltd, Director of Flex-G Pty Ltd, Trustee Director of Griffin Accelerator Holdings Pty Ltd and an Honorary Adjunct Professor at the University of Adelaide.
Raymond Whitaker, PhD
General Partner of EuclidSR Partners. Before joining EuclidSR Partners, Raymond
spent seven years at S. R. One, Limited , SmithKline Beecham's venture investing
arm. Prior to that, he was Director of Worldwide Business Development at SmithKline Beecham . His diverse experience also includes previous positions at Recordati SpA , Italy; Laboratoires Delagrange, France; and IDA, Ireland. Raymond received his Ph.D. in Biochemistry as well as his M.B.A. from the National University of Ireland , University College, Dublin.